Latest On Opiant Pharmaceuticals, Inc (OPNT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-11 06:12 EST | News | What's The Opiant CVR Worth? | N/A |  |
| 2023-01-26 23:40 EST | News | Horizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update) | N/A | |
| 2023-01-20 08:58 EST | News | Opiant wins FDA priority review for opioid overdose therapy | N/A | |
| 2023-01-14 01:31 EST | News | Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In | N/A | |
| 2022-11-14 13:17 EST | News | Opiant Pharmaceuticals GAAP EPS of -$1.93 misses by $0.42, revenue of $0.2M misses by $3.48M | N/A | |
| 2022-11-14 13:17 EST | News | Opiant surges 123% as Indivior set to acquire overdose therapy maker for $145M | N/A | |
| 2022-08-12 23:26 EST | News | Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-12 06:20 EST | News | Opiant Pharmaceuticals GAAP EPS of -$2.31 misses by $0.95, revenue of $3.89M misses by $0.77M | N/A | |
| 2022-08-10 21:44 EST | News | Opiant Pharmaceuticals Q2 Earnings Preview | N/A | |
| 2022-08-09 06:22 EST | News | Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment | N/A | |
| 2022-06-08 23:09 EST | News | Opiant, Aptar expand collaboration for the making of Unidose nasal spray for OPNT003 | N/A | |
| 2022-05-14 20:56 EST | News | Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-11 07:38 EST | News | Opiant Pharmaceuticals GAAP EPS of -$2.43 misses by $1.68, revenue of $4.47M misses by $1.43M | N/A | |
| 2022-05-10 11:36 EST | News | Opiant Pharmaceuticals Q1 Earnings Preview | N/A | |
| 2022-04-30 05:09 EST | News | Opiant denies licensing deal for opioid overdose therapy | N/A | |
| 2022-04-28 17:37 EST | News | Opiant opioid overdose candidate namalfene demonstrates non-inferiority to naloxone | N/A | |
| 2022-04-28 02:06 EST | News | Opiant says pharmacodynamic study shows benefit of its opioid overdose treatment OPNT003 | N/A | |
| 2022-03-22 00:17 EST | News | Opiant Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-16 08:15 EST | News | Opiant Pharmaceuticals GAAP EPS of $0.11 beats by $0.01, revenue of $13.8M beats by $0.54M | N/A | |
| 2022-03-16 08:14 EST | News | Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal On Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-15 07:39 EST | News | Opiant Pharmaceuticals Q4 Earnings Preview | N/A | |
| 2022-02-08 22:39 EST | News | Opiant Pharmaceuticals briefly spikes on takeover speculation | N/A | |
| 2022-01-25 00:46 EST | News | Opiant to get additional $2.2M from BARDA for OPNT003 to treat opioid overdose | N/A | |
| 2021-11-12 06:27 EST | News | Opiant Pharmaceuticals EPS beats by $0.35, beats on revenue | N/A | |
| 2021-11-12 06:27 EST | News | Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-11 11:02 EST | News | Opiant Pharmaceuticals Q3 2021 Earnings Preview | N/A | |
| 2021-11-05 11:25 EST | News | Opiant gets FDA fast track status for OPNT003 for treatment of opioid overdose | N/A | |
| 2021-09-22 02:58 EST | News | Opiant Pharmaceuticals: Assessing Recent Insider Buying | N/A | |
| 2021-08-07 23:01 EST | News | Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-06 08:28 EST | News | Opiant Pharmaceuticals EPS beats by $0.59, beats on revenue | N/A | |
| 2021-07-21 18:46 EST | News | Opiant shares soar 35% on OPNT003 opioid overdose study results | N/A | |
| 2021-04-06 07:19 EST | News | Opiant Pharmaceuticals starts dosing in OPNT003 study | N/A | |
| 2021-04-01 02:05 EST | News | Opiant Pharmaceuticals awarded final tranche of NIDA grant | N/A | |
| 2021-03-08 00:14 EST | Earnings Estimate | An EPS average of -$0.70 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2021-03-08 00:14 EST | Earnings Estimate | An EPS average of $0.82 is estimated for the 2022 year. | Buy | |
| 2021-03-08 00:14 EST | Earnings Estimate | An EPS average of -$0.32 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-03-07 08:18 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-05 03:00 EST | News | Opiant Pharmaceuticals EPS misses by $0.23, beats on revenue | N/A | |
| 2021-03-05 02:59 EST | News | Opiant Pharmaceuticals' (OPNT) CEO Roger Crystal on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-10 16:32 EST | News | Opiant's confirmatory pharmacokinetic study of OPNT003 gets underway | N/A | |
| 2020-12-14 23:14 EST | News | Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003 | N/A | |
| 2020-12-10 16:33 EST | News | Opiant Pharmaceuticals receives $50M in convertible debt financing | N/A | |
| 2020-11-26 21:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 13:06 EST | Analyst Rating | The Analyst Target Price has increased from $40 to $41.33. | Buy | |
| 2020-11-17 12:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 06:17 EST | News | Opiant Pharmaceuticals EPS beats by $0.36, beats on revenue | N/A | |
| 2020-11-13 06:17 EST | News | Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-08 00:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 16:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-03 12:27 EST | Financials | Company financials have been released. | Neutral | |
About Opiant Pharmaceuticals, Inc (OPNT):
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
General
- Name Opiant Pharmaceuticals, Inc
- Symbol OPNT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 30
- Last Split Factor1:100
- Last Split Date2014-12-31
- Fiscal Year EndJuly
- IPO Date2016-01-04
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.opiant.com
View More
Valuation
- Trailing PE 4.43
- Forward PE 26.74
- Price/Sales (Trailing 12 Mt.) 1.74
- Price/Book (Most Recent Quarter) 1.46
- Enterprise Value Revenue 0.76
- Enterprise Value EBITDA 0.33
View More
Financials
- Most Recent Quarter 2020-10-31
- Profit Margin -6%
- Operating Margin -8%
- Return on Assets -3%
- Return on Equity -5%
- Revenue 29.63 million
- Earnings Per Share $1.79
- Revenue Per Share $6.97
- Gross Profit 14.19 million
- Quarterly Earnings Growth 29.4%
View More
Highlights
- Market Capitalization 47.04 million
- EBITDA 9.49 million
- Analyst Target Price $41.33
- Book Value Per Share $8.34
View More
Share Statistics
- Shares Outstanding 4.29 million
- Shares Float 3.87 million
- % Held by Insiders 567%
- % Held by Institutions 31.07%
- Shares Short 10798
- Shares Short Prior Month 10123
- Short Ratio 0.18
View More
Technicals
- Beta 0.8
- 52 Week High $14.98
- 52 Week Low $6.79
- 50 Day Moving Average 12.64
- 200 Day Moving Average 9.29
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Opiant Pharmaceuticals, Inc (OPNT) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Opiant Pharmaceuticals, Inc (OPNT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2021-01-31 | 2021-03-04 | -$0.16 | $0.07 | -318.28% | |
| 2020-10-31 | 2020-11-12 | $N/A | $0.15 | -$0.21 | 172.57% |
| 2020-07-31 | 2020-08-06 | $N/A | -$0.05 | -$0.24 | 79.45% |
| 2020-04-30 | 2020-05-12 | $N/A | -$0.40 | -$0.19 | -106.93% |
| 2020-01-31 | 2020-03-04 | $N/A | $0.20 | $0.18 | 11.11% |
| 2019-10-31 | 2019-11-12 | $N/A | $1.97 | -$0.13 | 1615.38% |
| 2019-07-31 | 2019-08-08 | $N/A | $0.31 | -$0.55 | 156.03% |
| 2019-04-30 | 2019-05-09 | $N/A | -$0.44 | -$0.79 | 44.3% |
| 2019-01-31 | 2019-03-21 | $5.44 million | -$0.37 | -$0.13 | -184.62% |
| 2018-10-31 | 2018-11-07 | $4.76 million | -$0.32 | -$0.26 | -25.49% |
| 2018-07-31 | 2018-08-09 | $4.37 million | -$0.52 | -$1.17 | 55.36% |
| 2018-04-30 | 2018-05-08 | $3.15 million | -$3.68 | -$0.29 | -1168.97% |
| 2018-01-31 | 2018-03-07 | $1.7 million | -$3.68 | ||
| 2017-07-31 | 2017-10-13 | $3.77 million | -$0.17 | -$0.87 | 80.46% |
| 2017-04-30 | 2017-06-14 | $18000 | -$1.55 | -$0.82 | -89.02% |
| 2017-01-31 | 2017-03-15 | $13.54 million | $4.91 | -$0.85 | 677.65% |
| 2016-10-31 | 2016-12-15 | $1.12 million | -$0.30 | -$1.17 | 74.36% |
| 2016-07-31 | 2016-10-28 | $313000 | -$0.52 | -$1.52 | 65.79% |
| 2016-04-30 | 2016-06-08 | $2.61 million | $0.15 | ||
| 2016-01-31 | 2016-03-15 | $6.86 million | $1.52 | ||
| 2015-10-31 | 2015-12-14 | $120000 | -$6.00 | ||
| 2015-07-31 | 2015-10-26 | $870000 | -$0.41 | ||
| 2015-04-30 | 2015-04-30 | $120000 | -$1.01 | ||
| 2015-01-31 | 2015-01-31 | $560000 | -$1.54 | ||
| 2014-10-31 | 2014-10-31 | $N/A | -$0.43 | ||
| 2014-07-31 | 2014-07-31 | $N/A | -$2.33 | ||
| 2014-04-30 | 2014-04-30 | $N/A | -$0.31 | ||
| 2014-01-31 | 2014-01-31 | $N/A | -$2.96 | ||
| 2013-10-31 | 2013-10-31 | $N/A | -$1.03 | ||
| 2013-07-31 | 2013-07-31 | $N/A | -$1.34 | ||
| 2013-04-30 | 2013-04-30 | $N/A | -$0.83 | ||
| 2013-01-31 | 2013-01-31 | $N/A | -$0.43 | ||
| 2012-10-31 | 2012-10-31 | $N/A | -$0.65 | ||
| 2012-07-31 | 2012-07-31 | $N/A | -$1.60 | ||
| 2012-04-30 | 2012-04-30 | $N/A | -$1.15 | ||
| 2012-01-31 | 2012-01-31 | $N/A | -$3.91 | ||
| 2011-10-31 | 2011-10-31 | $N/A | -$4.42 | ||
| 2011-07-31 | 2011-07-31 | $N/A | -$3.47 | ||
| 2011-04-30 | 2011-04-30 | $N/A | -$7.28 | ||
| 2011-01-31 | 2011-01-31 | $N/A | -$1.47 | ||
| 2010-10-31 | 2010-10-31 | $N/A | -$0.46 | ||
| 2010-07-31 | 2010-07-31 | $N/A | -$0.56 | ||
| 2010-04-30 | 2010-04-30 | $N/A | -$0.23 | ||
| 2010-01-31 | 2010-01-31 | $N/A | -$1.09 |
Opiant Pharmaceuticals, Inc (OPNT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Opiant Pharmaceuticals, Inc (OPNT) Chart:
Opiant Pharmaceuticals, Inc (OPNT) News:
Below you will find a list of latest news for Opiant Pharmaceuticals, Inc (OPNT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Opiant Pharmaceuticals, Inc (OPNT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest OPNT Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:38 PM EST | 31 | $11.01 |
| Jun 13, 2022 7:41 PM EST | 1 | $11.14 |
| Jun 13, 2022 7:58 PM EST | 5 | $11.08 |
| Jun 13, 2022 7:59 PM EST | 100 | $10.91 |
| Jun 13, 2022 7:59 PM EST | 5 | $10.88 |
Opiant Pharmaceuticals, Inc (OPNT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000083/0001385508-20-000083-index.htm |
| 2012-11-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1108924/000000000012064464/0000000000-12-064464-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1385508/000092189520000507/0000921895-20-000507-index.htm |
| 2013-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1108924/000093247113002597/0000932471-13-002597-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1385508/000093583620000117/0000935836-20-000117-index.htm |
| 2012-12-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1108924/000114420412069987/0001144204-12-069987-index.htm |
| 2012-12-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1108924/000114420412069989/0001144204-12-069989-index.htm |
| 2012-12-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000118143112065624/0001181431-12-065624-index.htm |
| 2012-12-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000118143112065632/0001181431-12-065632-index.htm |
| 2012-12-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000118143112065639/0001181431-12-065639-index.htm |
| 2012-12-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000118143112065641/0001181431-12-065641-index.htm |
| 2012-07-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1108924/000119312512318806/0001193125-12-318806-index.htm |
| 2012-07-27 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1108924/000119312512318814/0001193125-12-318814-index.htm |
| 2012-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1108924/000119312512340861/0001193125-12-340861-index.htm |
| 2012-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1108924/000119312512341441/0001193125-12-341441-index.htm |
| 2012-09-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1108924/000119312512389599/0001193125-12-389599-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439884/0001193125-12-439884-index.htm |
| 2012-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439899/0001193125-12-439899-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439900/0001193125-12-439900-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439917/0001193125-12-439917-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439919/0001193125-12-439919-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439925/0001193125-12-439925-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439928/0001193125-12-439928-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439931/0001193125-12-439931-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439937/0001193125-12-439937-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439941/0001193125-12-439941-index.htm |
| 2012-10-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512439952/0001193125-12-439952-index.htm |
| 2012-10-30 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512441512/0001193125-12-441512-index.htm |
| 2012-10-31 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512443746/0001193125-12-443746-index.htm |
| 2012-11-01 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512444491/0001193125-12-444491-index.htm |
| 2012-11-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512447178/0001193125-12-447178-index.htm |
| 2012-11-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512447293/0001193125-12-447293-index.htm |
| 2012-11-02 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512449032/0001193125-12-449032-index.htm |
| 2012-11-06 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1108924/000119312512454885/0001193125-12-454885-index.htm |
| 2012-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1108924/000119312512457833/0001193125-12-457833-index.htm |
| 2012-11-14 | SC TO-T | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512468850/0001193125-12-468850-index.htm |
| 2012-11-14 | SC 14D9 | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1108924/000119312512468890/0001193125-12-468890-index.htm |
| 2012-11-15 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1108924/000119312512471191/0001193125-12-471191-index.htm |
| 2012-11-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512473067/0001193125-12-473067-index.htm |
| 2012-11-16 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512473209/0001193125-12-473209-index.htm |
| 2012-11-21 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1108924/000119312512478990/0001193125-12-478990-index.htm |
| 2012-11-28 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512483787/0001193125-12-483787-index.htm |
| 2012-11-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512484651/0001193125-12-484651-index.htm |
| 2012-11-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512484656/0001193125-12-484656-index.htm |
| 2012-11-29 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512484658/0001193125-12-484658-index.htm |
| 2012-12-03 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1108924/000119312512487961/0001193125-12-487961-index.htm |
| 2012-12-03 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512488218/0001193125-12-488218-index.htm |
| 2012-12-03 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1108924/000119312512489282/0001193125-12-489282-index.htm |
| 2012-12-05 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1108924/000119312512491048/0001193125-12-491048-index.htm |
| 2012-12-05 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512491054/0001193125-12-491054-index.htm |
| 2012-12-05 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1108924/000119312512491254/0001193125-12-491254-index.htm |
| 2012-12-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1108924/000119312512491261/0001193125-12-491261-index.htm |
| 2012-12-07 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512495329/0001193125-12-495329-index.htm |
| 2012-12-18 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512505612/0001193125-12-505612-index.htm |
| 2012-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1108924/000119312512506624/0001193125-12-506624-index.htm |
| 2012-12-18 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1108924/000119312512506683/0001193125-12-506683-index.htm |
| 2012-12-18 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1108924/000119312512506690/0001193125-12-506690-index.htm |
| 2012-12-18 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1108924/000119312512506694/0001193125-12-506694-index.htm |
| 2012-12-18 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1108924/000119312512506703/0001193125-12-506703-index.htm |
| 2012-12-18 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1108924/000119312512506710/0001193125-12-506710-index.htm |
| 2012-12-19 | SC 14D9/A | Solicitation, recommendation statements | https://www.sec.gov/Archives/edgar/data/1108924/000119312512506975/0001193125-12-506975-index.htm |
| 2012-12-21 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1108924/000119312512510792/0001193125-12-510792-index.htm |
| 2012-12-31 | 15-12G | Securities registration termination [Section 12(g)] | https://www.sec.gov/Archives/edgar/data/1108924/000119312512518791/0001193125-12-518791-index.htm |
| 2012-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058759/0001209191-12-058759-index.htm |
| 2012-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058760/0001209191-12-058760-index.htm |
| 2012-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058761/0001209191-12-058761-index.htm |
| 2012-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058762/0001209191-12-058762-index.htm |
| 2012-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058763/0001209191-12-058763-index.htm |
| 2012-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058920/0001209191-12-058920-index.htm |
| 2012-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000010/0001242665-12-000010-index.htm |
| 2012-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000011/0001242665-12-000011-index.htm |
| 2012-09-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000012/0001242665-12-000012-index.htm |
| 2012-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000013/0001242665-12-000013-index.htm |
| 2012-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000014/0001242665-12-000014-index.htm |
| 2012-09-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000015/0001242665-12-000015-index.htm |
| 2012-11-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000016/0001242665-12-000016-index.htm |
| 2012-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000017/0001242665-12-000017-index.htm |
| 2012-11-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000018/0001242665-12-000018-index.htm |
| 2012-11-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000019/0001242665-12-000019-index.htm |
| 2012-12-19 | 25-NSE | Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or ret | https://www.sec.gov/Archives/edgar/data/1108924/000135445712000286/0001354457-12-000286-index.htm |
| 2019-09-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000095/0001385508-19-000095-index.htm |
| 2019-09-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000096/0001385508-19-000096-index.htm |
| 2019-10-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000098/0001385508-19-000098-index.htm |
| 2019-11-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000100/0001385508-19-000100-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000107/0001385508-19-000107-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000109/0001385508-19-000109-index.htm |
| 2019-11-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000113/0001385508-19-000113-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000114/0001385508-19-000114-index.htm |
| 2019-11-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000117/0001385508-19-000117-index.htm |
| 2019-11-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000119/0001385508-19-000119-index.htm |
| 2019-11-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000121/0001385508-19-000121-index.htm |
| 2019-12-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000123/0001385508-19-000123-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000125/0001385508-19-000125-index.htm |
| 2019-12-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000127/0001385508-19-000127-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000002/0001385508-20-000002-index.htm |
| 2020-01-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000006/0001385508-20-000006-index.htm |
| 2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000009/0001385508-20-000009-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000011/0001385508-20-000011-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000013/0001385508-20-000013-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000015/0001385508-20-000015-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000017/0001385508-20-000017-index.htm |
| 2020-01-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000019/0001385508-20-000019-index.htm |
| 2020-02-06 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000022/0001385508-20-000022-index.htm |
| 2020-02-06 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000023/0001385508-20-000023-index.htm |
| 2020-02-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000025/0001385508-20-000025-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000030/0001385508-20-000030-index.htm |
| 2020-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000037/0001385508-20-000037-index.htm |
| 2020-03-04 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000039/0001385508-20-000039-index.htm |
| 2020-03-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000041/0001385508-20-000041-index.htm |
| 2020-03-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000044/0001385508-20-000044-index.htm |
| 2020-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000046/0001385508-20-000046-index.htm |
| 2020-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000048/0001385508-20-000048-index.htm |
| 2020-05-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000056/0001385508-20-000056-index.htm |
| 2020-05-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000057/0001385508-20-000057-index.htm |
| 2020-05-21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000059/0001385508-20-000059-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000061/0001385508-20-000061-index.htm |
| 2020-06-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000063/0001385508-20-000063-index.htm |
| 2020-06-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000065/0001385508-20-000065-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000067/0001385508-20-000067-index.htm |
| 2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000069/0001385508-20-000069-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000071/0001385508-20-000071-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000073/0001385508-20-000073-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000075/0001385508-20-000075-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000077/0001385508-20-000077-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000079/0001385508-20-000079-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000081/0001385508-20-000081-index.htm |
| 2020-06-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000083/0001385508-20-000083-index.htm |
| 2020-07-13 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000085/0001385508-20-000085-index.htm |
| 2020-07-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000087/0001385508-20-000087-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000093/0001385508-20-000093-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000094/0001385508-20-000094-index.htm |
| 2020-09-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000096/0001385508-20-000096-index.htm |
| 2020-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000100/0001385508-20-000100-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1385508/000138713120001748/0001387131-20-001748-index.htm |
| 2012-07-27 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/1108924/999999999712012355/9999999997-12-012355-index.htm |
Opiant Pharmaceuticals, Inc (OPNT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Opiant Pharmaceuticals, Inc (OPNT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 567%Institutional Ownership: 3107%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2012-12-18 | ALAIN J COHEN | President & Chief Tech Officer | Sell | 1,399.00 | 41.78 | 58,450.22 | 0.00 | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058760/0001209191-12-058760-index.htm |
| 2012-12-18 | MARC A COHEN | Chairman, CEO, Treas & Secy | Sell | 5,290.00 | 41.78 | 221,016.20 | 0.00 | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058761/0001209191-12-058761-index.htm |
| 2012-12-18 | Melvin III Wesley | Chief Financial Officer | Sell | 24,516.00 | 41.78 | 1,024,278.48 | 0.00 | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058763/0001209191-12-058763-index.htm |
| 2019-10-03 | Phil Skolnick | Chief Scientific Officer | Sell | 1,609.00 | 14.27 | 22,960.43 | 0.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000098/0001385508-19-000098-index.htm |
| 2019-11-05 | Phil Skolnick | Chief Scientific Officer | Sell | 2,500.00 | 14.89 | 37,225.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000100/0001385508-19-000100-index.htm |
| 2019-12-06 | Phil Skolnick | Chief Scientific Officer | Sell | 800.00 | 13.34 | 10,672.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000125/0001385508-19-000125-index.htm |
| 2012-12-18 | RONALD W KAISER | Director | Sell | 3,000.00 | 41.78 | 125,340.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058920/0001209191-12-058920-index.htm |
| 2012-12-18 | STEVEN G FINN | Director | Sell | 3,000.00 | 41.78 | 125,340.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058759/0001209191-12-058759-index.htm |
| 2012-12-18 | WILLIAM F STASIOR | Director | Sell | 3,000.00 | 41.78 | 125,340.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058762/0001209191-12-058762-index.htm |
| 2019-12-12 | Ann L. MacDougall | Director | Buy | 5,000.00 | 14.54 | 72,700.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000127/0001385508-19-000127-index.htm |
| 2019-10-01 | Phil Skolnick | Chief Scientific Officer | Buy | 10,000.00 | 9.00 | 90,000.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000098/0001385508-19-000098-index.htm |
| 2019-11-01 | Phil Skolnick | Chief Scientific Officer | Buy | 10,000.00 | 9.00 | 90,000.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000100/0001385508-19-000100-index.htm |
| 2019-12-02 | Phil Skolnick | Chief Scientific Officer | Buy | 10,000.00 | 9.00 | 90,000.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000123/0001385508-19-000123-index.htm |
| 2020-01-02 | Phil Skolnick | Chief Scientific Officer | Buy | 10,000.00 | 9.00 | 90,000.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000002/0001385508-20-000002-index.htm |
| 2020-01-07 | Phil Skolnick | Chief Scientific Officer | Buy | 4,150.00 | 10,035.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000015/0001385508-20-000015-index.htm | ||
| 2012-11-01 | STEVEN G FINN | Director | Buy | 15,000.00 | 15.42 | 231,300.00 | 106,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000016/0001242665-12-000016-index.htm |
| 2012-09-04 | WILLIAM F STASIOR | Director | Buy | 10,000.00 | 8.61 | 86,100.00 | 110,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000012/0001242665-12-000012-index.htm |
| 2012-09-10 | WILLIAM F STASIOR | Director | Buy | 3,000.00 | 113,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000014/0001242665-12-000014-index.htm | ||
| 2012-11-01 | STEVEN G FINN | Director | Buy | 10,000.00 | 13.25 | 132,500.00 | 116,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000016/0001242665-12-000016-index.htm |
| 2020-06-15 | Ann L. MacDougall | Director | Buy | 2,000.00 | 12,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000073/0001385508-20-000073-index.htm | ||
| 2012-11-06 | WILLIAM F STASIOR | Director | Buy | 15,000.00 | 15.42 | 231,300.00 | 128,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000018/0001242665-12-000018-index.htm |
| 2020-01-07 | David D O'Toole | Chief Financial Officer | Buy | 4,150.00 | 13,365.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000017/0001385508-20-000017-index.htm | ||
| 2012-11-06 | WILLIAM F STASIOR | Director | Buy | 10,000.00 | 13.25 | 132,500.00 | 138,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000018/0001242665-12-000018-index.htm |
| 2020-05-26 | David D O'Toole | Chief Financial Officer | Buy | 1,000.00 | 11.00 | 11,000.00 | 14,365.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000061/0001385508-20-000061-index.htm |
| 2020-06-11 | David D O'Toole | Chief Financial Officer | Buy | 1,000.00 | 8.74 | 8,740.00 | 15,365.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000067/0001385508-20-000067-index.htm |
| 2019-10-02 | Phil Skolnick | Chief Scientific Officer | Sell | 1,102.00 | 14.57 | 16,056.14 | 1,609.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000098/0001385508-19-000098-index.htm |
| 2019-11-22 | Gabrielle Alison Silver | Director | Buy | 1,785.00 | 13.51 | 24,115.35 | 1,785.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000119/0001385508-19-000119-index.htm |
| 2019-09-12 | Richard J Daly | Director | Buy | 1,800.00 | 13.90 | 25,020.00 | 1,800.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000030/0001385508-20-000030-index.htm |
| 2020-06-15 | Craig A Collard | Director | Buy | 2,000.00 | 2,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000071/0001385508-20-000071-index.htm | ||
| 2020-06-15 | Thomas T. Thomas | Director | Buy | 2,000.00 | 2,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000075/0001385508-20-000075-index.htm | ||
| 2020-01-07 | ROGER CRYSTAL | Chief Executive Officer | Buy | 13,650.00 | 22,125.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000011/0001385508-20-000011-index.htm | ||
| 2019-11-04 | Phil Skolnick | Chief Scientific Officer | Sell | 299.00 | 15.28 | 4,568.72 | 2,500.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000100/0001385508-19-000100-index.htm |
| 2019-10-01 | Phil Skolnick | Chief Scientific Officer | Sell | 7,289.00 | 14.79 | 107,804.31 | 2,711.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000098/0001385508-19-000098-index.htm |
| 2012-06-13 | MARC A COHEN | Chairman,CEO,Treas, & Sec | Sell | 12,000.00 | 24.32 | 291,840.00 | 2,718,222.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000011/0001242665-12-000011-index.htm |
| 2012-06-13 | MARC A COHEN | Chairman,CEO,Treas, & Sec | Buy | 12,000.00 | 5.85 | 70,200.00 | 2,730,222.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000011/0001242665-12-000011-index.htm |
| 2012-06-14 | MARC A COHEN | Chairman,CEO,Treas, & Sec | Sell | 12,323.00 | 24.68 | 304,131.64 | 2,743,899.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000011/0001242665-12-000011-index.htm |
| 2012-06-14 | MARC A COHEN | Chairman,CEO,Treas, & Sec | Buy | 38,000.00 | 5.85 | 222,300.00 | 2,756,222.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000011/0001242665-12-000011-index.htm |
| 2012-11-14 | MARC A COHEN | Chairman,CEO,Treas, & Sec | Buy | 48,000.00 | 11.75 | 564,000.00 | 2,791,899.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000019/0001242665-12-000019-index.htm |
| 2019-11-01 | Phil Skolnick | Chief Scientific Officer | Sell | 7,201.00 | 15.10 | 108,735.10 | 2,799.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000100/0001385508-19-000100-index.htm |
| 2019-12-03 | Phil Skolnick | Chief Scientific Officer | Sell | 4,578.00 | 13.93 | 63,771.54 | 2,857.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000123/0001385508-19-000123-index.htm |
| 2012-10-29 | Melvin III Wesley | Chief Financial Officer | Buy | 13,333.00 | 9.79 | 130,530.07 | 33,259.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000017/0001242665-12-000017-index.htm |
| 2020-06-15 | Richard J Daly | Director | Buy | 2,000.00 | 3,800.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000079/0001385508-20-000079-index.htm | ||
| 2012-06-06 | RONALD W KAISER | Director | Sell | 10,000.00 | 26.04 | 260,400.00 | 40,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000010/0001242665-12-000010-index.htm |
| 2020-01-07 | Phil Skolnick | Chief Scientific Officer | Sell | 3,043.00 | 13.36 | 40,654.48 | 4,150.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000015/0001385508-20-000015-index.htm |
| 2012-09-10 | RONALD W KAISER | Director | Buy | 3,000.00 | 43,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000015/0001242665-12-000015-index.htm | ||
| 2020-09-03 | Thomas T. Thomas | Director | Buy | 2,500.00 | 8.40 | 21,000.00 | 4,500.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000096/0001385508-20-000096-index.htm |
| 2020-06-10 | Gabrielle Alison Silver | Director | Buy | 2,730.00 | 9.13 | 24,924.90 | 4,515.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000069/0001385508-20-000069-index.htm |
| 2012-12-18 | Melvin III Wesley | Chief Financial Officer | Buy | 26,667.00 | 9.79 | 261,069.93 | 46,295.00 | https://www.sec.gov/Archives/edgar/data/1108924/000120919112058763/0001209191-12-058763-index.htm |
| 2020-09-04 | Thomas T. Thomas | Director | Buy | 500.00 | 8.05 | 4,025.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000096/0001385508-20-000096-index.htm |
| 2012-06-06 | RONALD W KAISER | Director | Buy | 10,000.00 | 13.25 | 132,500.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000010/0001242665-12-000010-index.htm |
| 2020-01-07 | Phil Skolnick | Chief Scientific Officer | Sell | 2,900.00 | 13.60 | 39,440.00 | 5,885.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000015/0001385508-20-000015-index.htm |
| 2020-06-15 | Gabrielle Alison Silver | Director | Buy | 2,000.00 | 6,515.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000077/0001385508-20-000077-index.htm | ||
| 2020-06-15 | Sinclair Michael | Director | Buy | 2,000.00 | 71,220.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000081/0001385508-20-000081-index.htm | ||
| 2020-01-08 | Phil Skolnick | Chief Scientific Officer | Sell | 2,842.00 | 13.46 | 38,253.32 | 7,193.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000015/0001385508-20-000015-index.htm |
| 2019-12-02 | Phil Skolnick | Chief Scientific Officer | Sell | 2,565.00 | 14.17 | 36,346.05 | 7,435.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000123/0001385508-19-000123-index.htm |
| 2019-12-05 | Phil Skolnick | Chief Scientific Officer | Sell | 2,057.00 | 13.74 | 28,263.18 | 800.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000125/0001385508-19-000125-index.htm |
| 2020-01-06 | Phil Skolnick | Chief Scientific Officer | Sell | 515.00 | 13.80 | 7,107.00 | 8,785.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000002/0001385508-20-000002-index.htm |
| 2012-09-10 | STEVEN G FINN | Director | Buy | 10,000.00 | 8.61 | 86,100.00 | 88,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000013/0001242665-12-000013-index.htm |
| 2019-11-15 | David D O'Toole | Chief Financial Officer | Buy | 1,000.00 | 14.91 | 14,910.00 | 9,015.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000117/0001385508-19-000117-index.htm |
| 2012-09-10 | STEVEN G FINN | Director | Buy | 3,000.00 | 91,000.00 | https://www.sec.gov/Archives/edgar/data/1108924/000124266512000013/0001242665-12-000013-index.htm | ||
| 2019-11-15 | David D O'Toole | Chief Financial Officer | Buy | 100.00 | 15.00 | 1,500.00 | 9,115.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000117/0001385508-19-000117-index.htm |
| 2019-11-26 | David D O'Toole | Chief Financial Officer | Buy | 100.00 | 13.22 | 1,322.00 | 9,215.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550819000121/0001385508-19-000121-index.htm |
| 2020-01-02 | Phil Skolnick | Chief Scientific Officer | Sell | 700.00 | 14.08 | 9,856.00 | 9,300.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000002/0001385508-20-000002-index.htm |
| 2020-01-07 | Mark Jason Heath Ellison | Insider | Buy | 4,150.00 | 9,680.00 | https://www.sec.gov/Archives/edgar/data/1385508/000138550820000013/0001385508-20-000013-index.htm |